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ABSTRACT 
Importance: Age appropriateness of anticoagulants for stroke prevention in atrial fibrillation (AF) is uncertain. 
Objective: To review oral anticoagulants (OAC) for AF in older (age >65y) people, to classify appropriate and 
inappropriate drugs based on efficacy, safety and tolerability using the Fit- fOR-The-Aged (FORTA) 
classification.  
Evidence: We performed a structured comprehensive review of controlled clinical trials and summaries of 
individual product characteristics to assess study and total patient numbers, quality of major outcome data and 
data of geriatric relevance. The resulting evidence was discussed in a round table with an interdisciplinary panel 
of ten European experts. Decisions on age appropriateness were made using a Delphi process.  
Findings: For the 8 drugs included, 380 citations were identified. The primary outcome results were reported in 
32 clinical trials with explicit and relevant data on older people. Though over 24000 patients aged >75/80 were 
studied for warfarin, data on geriatric syndromes were rare (2 studies reporting on frailty/falls/mental status), and 
missing for all other compounds. Apixaban was rated FORTA-A (highly beneficial). Other non-vitamin K 
antagonist OACs [NOACs] (including low/high-intensity dabigatran and high-intensity edoxaban) and warfarin 
were assigned to FORTA-B (beneficial). Phenprocoumon, acenocoumarol and fluindione were rated FORTA-C 
(questionable) mainly reflecting the absence of data.  
Conclusions: All NOACs and warfarin were classified as beneficial or very beneficial in older persons (FORTA-
A or-B) underlining the overall positive assessment of the risk/benefit ratio for these drugs. For other vitamin-K-
antagonists regionally used in Europe the lack of evidence should challenge current practice. 
  
KEY WORDS 
Older people; Oral Anticoagulants; Atrial fibrillation; Effectiveness; Tolerability; FORTA Fit For The Aged. 
 
KEY POINTS 
 Age appropriateness of chronically used anticoagulants to treat atrial fibrillation is still uncertain. 
 Using a structured comprehensive approach including a literature search and subsequent Delphi process, 
an interdisciplinary expert group rated the appropriateness of oral anticoagulants for long-term treatment of atrial 
fibrillation in older people with regard to efficacy, tolerability, and safety.  
 In older people the majority of these drugs, the non-vitamin K oral anticoagulants and warfarin, are seen 
to be beneficial or very beneficial while regionally used older vitamin K antagonists should be used with caution 
as evidence is missing. 
 The evidence basis for the use of these drugs in older people regarding geriatric syndromes is very 
limited. 
 
 4 
 
1. INTRODUCTION 
Atrial fibrillation is an age related condition afflicting up to 2% of the general population [1] but up to about 13% 
in patients over 75 y [2]. It is a leading cause of morbidity and mortality due to stroke, but also a major risk for 
dementia [3]. Anticoagulation reduces embolic risk by more than half [4]. As prevalence of atrial fibrillation 
rises with age [3] anticoagulants are most often used in older people.  
Against the background of pharmacological complexity in older people the FORTA (Fit fOR The Aged) 
classification was introduced in 2008 with the aim of guiding physicians in their efforts to rapidly optimize and 
prioritize medications. FORTA is based on the  benefit, risk and appropriateness of drugs for older patients in 
everyday clinical settings [5, 6]. It represents the first classification system in which both negative (harmful or 
critical drugs, D and C labels) and positive (beneficial drugs, A and B labels) labelling is combined at the level 
of individual drug or drug groups. The system and the derived FORTA list ([7] updated February 2016 [8]) are 
based on individual indications (implicit listing depending on patient characteristics/diagnoses) and therefore 
differ from negative lists such as the Beers Criteria list [9]  which do not require intricate knowledge on patients 
(explicit lists [10]). In a randomized, controlled trial (VALFORTA) FORTA significantly improved medication 
quality as measured by the FORTA-score that adds over- and undertreatment errors. FORTA also reduced 
adverse drug effects at a number needed to treat of only 5 [11]. 
Here we present the rating process of an independent multiprofessional international expert panel for 8 oral 
anticoagulants (OAC) used to treat atrial fibrillation that was based on a structured comprehensive literature 
review and a subsequent two-step Delphi approach using the FORTA classification. 
 
2. METHODS  
2.1 Procedure 
   The present expert rating procedure was similar to that used to assess urological drugs earlier (for details see 
[12]). In brief, a structured comprehensive review on clinical trials providing relevant data for OACs used in 
older people was performed; based on this structured comprehensivereview 8 OACs were assessed and labelled 
by 10 raters (all authors + the initiator MW) according to the FORTA system.   
2.1.1 Structured comprehensiveliterature review 
A literature search in PubMed/Medline was performed from November 2015 through February 2016 using the 
search terms [drug name] [atrial fibrillation] in the INN terminology, plus the standard filters [randomized 
controlled trial] [full text available] [age 65+ years] (no language exclusion). The aim was to identify appropriate 
clinical trials to examine the efficacy, safety and tolerability of oral anticoagulants used for the treatment of atrial 
fibrillation in older people. Primary research questions were to assess study and total patient numbers, quality of 
major outcome data and data of geriatric relevance. Abstracts were retrieved and reviewed for appropriateness 
by MW, and rechecked. Randomized, controlled studies with > 100 patients exposed to the particular drug for at 
least 6 months providing relevant data on stroke and/or safety (major bleeding, intracranial bleeding or geriatric 
syndromes, e.g. frailty, falls, dementia) for treatments were included if abstracts pointed to such endpoints and 
the full paper proved to contain them, in particular whether the article explicitly reported results in age groups 
≥65years, ≥70 years, ≥75 years, ≥80 years or ≥85 years. Sub-analyses were only included if containing data on 
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the population searched for and those that were not reported in the primary paper. No other sources or primary 
data from investigators were included. The included studies were analysed for separate data on the group of 
older people which were recorded. Conflicts of interpretation would have been discussed further in the rater 
panel, but did not occur. Key information from appropriate articles was extracted into a Microsoft Word file with 
particular focus on the presence of information on geriatric syndromes (Table 1 of the electronic supplementary 
material (ESM)). By definition, only class 1 studies according to the Oxford Centre for Evidence-based 
Medicine were included ([13] individual RCT with narrow confidence interval). No meta-analysis of data was 
planned, rather summary values concerning effect/safety parameters were provided to the raters for their 
assessment. 
2.1.2 Identification of the raters 
The initiator of the project (MW) identified raters based on online information. Experts were eligible if they met 
the following criteria:  geriatricians or cardiologists with documented clinical experience in the pharmacotherapy 
of (multimorbid) older people; high academic status; prominent standing in the leading geriatric/cardiological 
medical associations; substantial number, quality and relevance of publications. Accordingly, ten raters from 7 
European countries were identified who met those criteria and could also accept the invitation to participate (the 
other authors). This number was between the preset minimum of 8 and maximum of 15 raters. 
2.1.3 Selection of drugs to be assessed 
In the first step, the initiator selected oral anticoagulants used in thromboembolic prevention for atrial 
fibrillation. The proposed choice of drugs was refined by the raters who voted for adding fluindione. The studied 
drugs were the vitamin K antagonists (VKAs) warfarin, phenprocoumon, acenocoumarol and fluindione, and all 
currently marketed non-vitamin K oral anticoagulants (NOACs): dabigatran, rivaroxaban, edoxaban and 
apixaban. The raters proposed dabigatran to be assessed for both the marketed high and the low intensity 
approach and edoxaban only for the licensed high intensity approach. 
2.1.4 Analysis of Summary of Product Characteristics 
The most recent summary of product characteristics (SmPC) was downloaded for all drugs from the EMA 
website, or if not available, from other reliable sources (e.g. www.fachinfo.de) or the producer. The texts were 
thoroughly analysed using the same template as above (Table 1 of the electronic supplementary material (ESM)).  
2.1.5 FORTA-labels 
From this material, the initiator derived a proposal for initial FORTA labels. The proposal together with the 
spreadsheet and full texts/abstracts were forwarded to the rater team for review and addition of further articles 
which were felt to be relevant. 
2.1.6 2-step Delphi process 
The initiator and the rater group convened in March, 2016; raters were instructed about the process with 
particular focus on the FORTA procedure. The evidence synthesis was presented and a round table discussion 
was chaired by MW. After the meeting, raters reviewed the literature, the structured comprehensive review, 
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classified each of the listed drugs according to FORTA, and had the option to provide comments in a survey 
form (Table 2 of the electronic supplementary material (ESM)). Rating was performed blinded to others’ scores. 
Results were collated and aggregate scores, along with anonymised comments were shared with the raters. 
Where consensus was not reached, raters were asked to resubmit scores.  
2.1.7 Delphi process, statistics 
Details of the Delphi method (all experts rate independently without knowing their peers’ ratings, knowing only 
the reached consensus) and the corresponding statistical analysis have been described in detail elsewhere [7, 12]. 
In brief, the international raters assessed the OAC after instruction about FORTA based on the structured 
comprehensive review and SmPCs. The aggregated list of raters’ labels was statistically analysed, the aggregate 
findings were sent out to the raters for a second rating round if the corrected consensus coefficient was <0.8. The 
raters’ FORTA labels were converted into numerical values A→1, B→2, C→3, and D→4, respectively; the 
arithmetic mean (m) was calculated for each item, reconverted to FORTA labels and compared with the original 
author-based labels.  
 
3. RESULTS 
3.1 Literature search 
380 abstracts were potentially relevant based on the search in PubMed/Medline. Figure 1 shows 32 papers 
identified from abstracts which met the inclusion criteria as checked in the full text (except for two abstracts); 
they contained results on clinical trials on older people or explicitly reported data from subgroups of older people 
aged ≥65 years (which is the most commonly used, but unauthorised definition of “elderly”) for the 8 drugs 
investigated. Explicit results on clinical trials for older patients were reported for all drugs except for 
phenprocoumon, acenocoumarol and fluindione. Table 1 shows the number of abstracts retrieved, the numbers of 
studies reporting data on older patients to support drug efficacy and safety, patients’ numbers and information on 
geriatric syndromes.  The drug with most patients studied is warfarin; for each NOAC several thousand older 
patients were studied as well in a grand total of 8 eligible studies to date. Information on geriatric syndromes was 
only available in three trials on warfarin, concerning mental status, falls or frailty. The hazard ratios or odds 
ratios, event rates, for the individual trials regarding efficacy and safety parameters as well as their comparators 
are compiled in Table 1 of the electronic supplementary material (ESM). Only one placebo-controlled trial of 
warfarin (the most studied drug) provided a subgroup analysis for both efficacy and safety on 616 patients >70 
years (AFFIRM trial [14]). All NOACs were compared to warfarin only, and superiority claimed for one 
(rivaroxaban), two (dabigatran, edoxaban) or all three (apixaban) major endpoints (stroke/systemic embolism; 
major bleeding; intracerebral bleeding) with noninferiority substantiated otherwise for all endpoints.  
 
3.2 Analysis of Summary of Product Characteristics 
All package inserts explicitly mentioned the elderly population. A summary is provided in Table 1 (see 
electronic supplementary material (ESM)). Information available on side effects and contraindications of 
particular interest in older populations (e.g. geriatric syndromes) was not found in any of the reviewed SmPC. 
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All contained precautions regarding renal function and high age in general; only for NOACs specific dosing 
recommendations exist reflecting renal function, and high age as such (dabigatran and apixaban). 
 
3.3 Delphi process leading to the final FORTA classification 
Final ratings as well as the individual score categories are shown in Table 2. Proposed ratings were confirmed in 
89% of cases (deviation for one out of 9 items); only for high intensity edoxaban the final result of B was 
different from the proposed A rating. Table 3 of the electronic supplementary material (ESM) compiles the 
raters’ comments. 
One of the 9 items had to be re-rated in the second survey (high intensity edoxaban). This was necessary as the 
first round resulted in 5 A and 5 B votes leading to a corrected consensus coefficient of 0.75. The second round 
resulted in 6 B, 4 A votes, and the final vote remained unchanged at B. 
For regionally used VKAs, 2-4 raters without experience on these VKA refrained from voting. 
Table 2 also summarizes the rationales (key points) behind the categorization of the individual drugs as derived 
from data and the raters’ comments given in Table 3 of the electronic supplementary material (ESM). 
Ratings were markedly different for e.g. warfarin (7 B, 3 C) and high intensity edoxaban (6 B, 4 A) yet leading 
to the same label B as the FORTA principle does not support intermediate values (for simplifying purposes). In 
contrast to this heterogeneity, apixaban was unanimously rated A by all ten raters. 
No item was assigned the FORTA D (Don’t) label. Three VKAs (phenprocoumon, acenocoumarol and 
fluindione) were labeled FORTA C, mainly reflecting the lack of study data in older people. This category 
indicates that it requires even more intense monitoring than that required for studied drugs. 
Warfarin, dabigatran, edoxaban and rivaroxaban were labeled B (beneficial) which means atrial fibrillation can 
be safely and effectively treated in older people, and this label affirms that it is standard to treat this condition. 
Apixaban was labeled A (absolutely) meaning it was seen as the drug with the most beneficial risk-benefit-ratio 
in this group. This differentiation was mainly based on the fact that endpoint superiority was most prominent for 
apixaban; either renal problems (dabigatran) or limited data on superiority (rivaroxaban, edoxaban) reduce the 
distance of these NOACs from warfarin so that it cannot be detected by FORTA as the number of categories is 
limited.  
 
4. DISCUSSION 
4.1 Strengths and weaknesses 
This structured comprehensive review for the first time confirmed the paucity or absence of data of geriatric 
importance in one of the most successful and important areas of drug treatment.  
Concerning weaknesses, inclusion was limited to studies >100 participants treated for a minimum of 6 months 
which, thus, may have missed smaller trials. Reporting of endpoints was heterogeneous, in particular for 
bleeding events, as were patient populations regarding comorbidities (e.g. reflected in CHADS2-or CHA2DS2-
VASc-scores) thus precluding quantitative comparisons. No attempts were made to obtain data on unpublished 
 8 
 
observations.  
If older subgroups were not explicitly reported in larger studies, these data remained excluded.  
Although SmPC were included to consider unpublished information, some valuable information from clinical 
studies may not have been detected by the screening procedure. The experiences from uncontrolled studies, real 
life cohort studies, registries or even case reports are lost in such an approach; they, however, may contain 
relevant information sometimes even triggering regulators actions (case series and “Dear doctor letters”). This is 
reflected by the considerable discrepancy between numbers of primarily identified and included abstracts, in 
particular for warfarin (237 over 24).  
 
The strength of the Delphi process is to bring opinions from different professional and regional backgrounds, 
into a quantitative rating process which is the typical strategy to assess treatments (and diagnostics) for which 
consensual elements are essential as evidence is sparse.  
Concerning weaknesses, the multidisciplinary nature of this Delphi exercise may result in biases and 
inconsistencies. For instance, not all of the raters had practical experience with all drugs (e.g. regionally used 
VKAs). Furthermore, the group was small, did not include key stake-holders (e.g. GPs, pharmacists) and experts 
from North America, and a larger set of experts might have rated differently. However, the degree of consensus 
(only one out of 9 items had to be re-rated) was remarkable as experts with different professional background 
voted without knowing their colleagues’ opinions. This is in line with the degree of rating consensus for the first 
round of the Delphi process for the published FORTA list, both in 2012 and 2015 [7, 8] which was almost the 
same (92%) for a much larger group of raters (20 from different countries).  
As the experts were instructed as a group about FORTA and the structured comprehensive review at the 
inaugural meeting, anonymity could not be warranted; conversely, this collective instruction ensured that rating 
was performed on the same basis of information. To further independence, communication of any opinion 
relevant to the voting was strongly discouraged (‘forbidden’) at this meeting, and a formal agreement was 
obtained on not communicating the individual votes between the experts during the Delphi rounds.  
Potential conflicts of interest together with industry sponsorship are openly listed below.  We consider that the 
methodology, procedure and approach were robust in minimising any potential bias of this origin. 
 
4.2 Key findings on oral anticoagulants appropriateness 
The results of the FORTA process show that, within a given drug class, the perceived appropriateness of 
individual drugs may substantially vary: the rating for oral anticoagulants range from C to A. Such differences 
can be based on proven differences in efficacy and safety (for example newer drugs may have better efficacy 
and/or safety), but also on the quality of the available trial(s), and the specific patient population studied. Such 
compelling evidence, as typically derived from RCTs, is an exception rather than the rule for the older 
population. Studies especially designed for older people may reflect specific outcomes of interest, for example, 
cognition or frailty aspects, rather than efficacy or tolerability. Such studies are typically even rarer, as discussed 
here for dementia: this pivotal geriatric condition and atrial fibrillation are clearly associated as shown in a recent 
metaanalysis and a cohort study [16,17] . Only 2 older studies on warfarin reported on cognitive function or falls 
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in relation to treatment [18, 19], but none for the other drugs. In an earlier uncontrolled trial even the hypothesis 
was derived that dementia may be prevented by warfarin [20], and a relation between anticoagulation control and 
dementia was reported [21]. A current metaanalysis suggests a possible cognitive benefit of anticoagulation [22]. 
Further noncontrolled studies exist such as that by Perera et al. or Lefebvre et al. [23, 24] showing that frail 
patients are at higher risk for bleeding. However, no comparison between drug and placebo supports the 
assessment of efficacy/safety here.  
Oral anticoagulation is often withheld in clinical practice due to risk of falls. One analysis suggests this risk 
might be overemphasised [25] though people who fall while on anticoagulation would also seem to have greater 
mortality [26]. This balance of degree of risk versus derived benefit of anticoagulation, in falling patients, 
requires further research.  
Thus, a major result of this structured comprehensive review is the fact that though older people are included in 
several RCTs, no relevant data on specific geriatric syndromes or side effects with geriatric relevance other than 
bleeding have been sufficiently studied and, thus, cannot be used to guide the FORTA assessment. Latter has 
consequently been based only on efficacy/safety data and use conditions (e.g. renal function, dosing regime), as 
in some cases only found in the SmPCs. 
This was the case for three VKAs: phenprocoumon which is almost exclusively used in Germany, fluindione 
only used in France and acenocoumarol used mainly in France. The lack of eligible studies was the basis for 
labelling them FORTA C: this category (cautious) is typical for drugs with potential risks that need to be applied 
under close surveillance as comparable study data are missing. Therefore, it is recommended to rethink current 
practice to use unstudied drugs in older people.  
Warfarin was seen as beneficial (FORTA B) as the overall positive impression is backed by studies in >26,000 
older people, and a strong indication to treat the disease in older patients is derived from the data on this 
particular drug. The assumption that warfarin is beneficial in older people is based on one subgroup analysis 
including 616 patients comparing warfarin to a matched group of patients not on warfarin [14]. A smaller 
placebo-controlled study involved 110 older patients on warfarin but only reported efficacy data [27]. Strictly 
spoken these 700 patients tells us that warfarin is useful in older people, and NOACs may be similarly or more 
efficacious and safe. Thus, the placebo-basis for the entire OAC data construct is very slim in the elderly.  
The NOACs were seen as either beneficial (B) or in one case very beneficial (A). They provide at least one 
(apixaban two) large trial containing thousands of older people. Efficacy and safety parameters were looked at 
specifically for older people, and superiority to warfarin seemed most consistent for apixaban. Superiority was 
seen for all important endpoints, major AND intracranial bleeding, all cause stroke prevention and mortality. 
Rivaroxaban though tested in a study with sicker patients only showed no superiority in those endpoints except 
for intracerebral bleeding which however also disappeared at age >75 years. Dabigatran at both dosing 
intensities was superior in either major bleeding or stroke prevention. Edoxaban (high intensity only) was safer, 
but not more efficacious than warfarin. Latter three NOACs were not seen to be better than warfarin in older 
people though the vote on edoxaban was closest to the A level.  
Some of those observational studies or registries cited above (e.g. [20-24]), but not included in this structured 
comprehensive  review, point to the importance of data from studies or even case reports not fulfilling inclusion 
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criteria of RCTs commonly required for such reviews. This instrument thus does not cover all evidences 
available, though even regulatory action including “dear doctor letters” may be triggered by these observations 
such as for bleeding complications of dabigatran treatment in 2011 in Germany [28]. The consensus process by 
experts in the field may offer some compensation for this deficiency as their experience and knowledge of the 
field should reflect major “other” evidence; of course this introduces  subjective reasoning, and just can only be 
seen as a weak remedy.  
 It is speculative to explain the endpoint differences for the NOACs; certainly, renal function is reduced at high 
age, and this is a particular concern for any drug with predominant renal excretion and narrow therapeutic index. 
In this context, dabigatran (renal excretion 80%), and maybe edoxaban (renal excretion 50%) have an age-related 
safety problem which may result in accumulation [29] in particular if renal dosing is not optimal. This feature, 
however, cannot explain all differences observed. 
In essence, the votes in this Delphi-process were mainly guided by the available endpoint data; it is an 
exceptional advantage of NOACs in this regard that – for atrial fibrillation - they were primarily tested in older 
people with average ages between 71 and 73 in the large phase III studies. Yet, as for warfarin specific data on 
geriatric syndromes are widely missing as none of these trials was specifically designed to meet the needs of a 
geriatric population, e.g. by including tests on mental function, frailty or fall risk. 
Bearing this in mind, FORTA does only reflect currently available data; it should be seen as a stimulus to fill the 
huge gaps in clinical data concerning older people, and if new data become available revisited. 
The absence of information on side effects and contraindications of particular relevance to older populations 
(e.g. geriatric syndromes) in any of the reviewed SmPC continues to be unacceptable. 
 
5. CONCLUSIONS 
    All NOACs and warfarin were classified as beneficial or very beneficial in older persons (FORTA A or B) 
underlining the overall positive assessment of the risk/benefit ratio for these drugs against available evidence. 
Differentiations between FORTA A and B were limited due to the restricted number of categories in this system, 
thus not reflecting distinct advantages or disadvantages in full. For other vitamin K antagonists (FORTA C) 
regionally used in Europe the lack of evidence should challenge current practice. 
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Legend Fig.1 
Flow diagram for the structured comprehensive review according to the PRISMA statement [15]
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  Abstracts Separate 
studies/entries 
fullfilling criteria 
Patients >65/70y Patients >75/80 y Info on geriatric syndromes 
Vitamin K 
antagonists 
     
Acenocoumarol 9 0 0 0 none 
Fluindione 1 0 0 0 none 
Phenprocoumon 8 0 0 0 none 
Warfarin 237 24 16443 24621 2 studies („MMSE similar in both 
groups“, „MMSE no difference 
between warfarin and ASS though 
trend 1.48 (0.56–3.91) p 0.42“) 
1 study: frailty/risk of falls as 
reasons for withdrawal 
Non-vitamin K oral 
anticoagulants 
     
Apixaban 35 2 4519 5005 none 
Dabigatran 37 1 5256 5318 none 
Edoxaban 11 1   5654 none 
Rivaroxaban 42 4 2366 6581 none 
 
 
Table 1 
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Results of the structured comprehensive review on oral anticoagulants; if not separated, patients may have 
been counted twice in the age categories  
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Drug 
FORTA 
classa 
FORTA 
A 
FORTA 
B 
FORTA 
C 
FORTA 
D 
Number
s of 
votesb 
Consensus 
coefficient. 
Round 1 
(cut-off 
0.800) 
Comments relevant for FORTA 
classification 
Acenocoumarol C   2 5   
7 0.857 
No clinical data, efficacy/safety 
unknown, high risk of interactions 
Fluindione C     5 1 
6 0.917 
No clinical data, efficacy/safety 
unknown, high risk of interactions 
Phenprocoumon C   2 6   
8 0.875 
No clinical data, efficacy/safety 
unknown though exposure of large 
patient groups without obvious 
disadvantages, high risk of interactions 
Warfarin B   7 3   
10 0.85 
Well studied, efficacy highly likely in 
elderly, safety concerns, monitoring 
need, evidence on geriatric syndromes 
still limited, inferiority to NOACs in 
certain conditions, high risk of 
interactions 
Dabigatran low 
B 3 7     
10 0.85 
Large study in elderly, efficacy/safety 
established with limited indications for 
superiority, low risk of interactions, 
significant renal problem, antidote 
available 
Dabigatran high 
B 3 7     
10 0.85 
Large study in elderly, efficacy/safety 
established with limited indications for 
superiority, low risk of interactions, 
significant renal problem, antidote 
available 
Edoxaban high  
                          
(A) B 
5 
4c 
5 
6 c 
    10 
10 c 
0.75 
 
Large study in elderly, efficacy/safety 
established with limited indications for 
superiority, low risk of interactions 
Rivaroxaban 
B 2 7 1   
10 0.85 
Large study in elderly, efficacy/safety 
established with the least indications for 
superiority, low risk of interactions 
Apixaban 
A 10       
10 1 
Two large studies in elderly, 
efficacy/safety established with 
convincing data on superiority in 
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multiple major endpoints including 
mortality, low risk of interactions 
 
Table 2 
Results of the two-step Delphi process to label oral anticoagulants according to the FORTA classification. 
The FORTA class is shown as well as the number of votes in each FORTA category. Comments were 
condensed from data, SMPCs and raters‘ comments shown in full in Table 1 and 3 of the electronic 
supplementary material (ESM). 
a: Proposed FORTA class in brackets if different from final result 
b: Number of abstentions equals difference to 10 
c: round 2 
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Fig. 1  
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